181 related articles for article (PubMed ID: 29720299)
1. Effects of Denosumab After Treatment Discontinuation : A Review of the Literature.
Iranikhah M; Deas C; Murphy P; Freeman MK
Consult Pharm; 2018 Mar; 33(3):142-151. PubMed ID: 29720299
[TBL] [Abstract][Full Text] [Related]
2. Retained Skeletal Effects of Zoledronic Acid Following Discontinuation of Treatment: A Review of the Literature.
Deas CM; Murphy P; Iranikhah M; Freeman MK
Consult Pharm; 2017 Mar; 32(3):144-155. PubMed ID: 28270269
[TBL] [Abstract][Full Text] [Related]
3. Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data.
Zheng J; van Schaick E; Wu LS; Jacqmin P; Perez Ruixo JJ
J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):333-47. PubMed ID: 26123919
[TBL] [Abstract][Full Text] [Related]
4. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
5. Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review.
Elbers LPB; Raterman HG; Lems WF
Drugs; 2021 Sep; 81(14):1645-1655. PubMed ID: 34524681
[TBL] [Abstract][Full Text] [Related]
6. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
7. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
8. Cancel the denosumab holiday.
McClung MR
Osteoporos Int; 2016 May; 27(5):1677-82. PubMed ID: 26932443
[No Abstract] [Full Text] [Related]
9. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
Uebelhart B; Rizzoli R; Ferrari SL
Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
[TBL] [Abstract][Full Text] [Related]
10. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
[TBL] [Abstract][Full Text] [Related]
11. Fracture Risk Following Discontinuation of Teriparatide: A Review of the Literature.
Murphy PZ; Iranikhah M; Deas CM; Freeman MK
Consult Pharm; 2018 Jul; 33(7):365-375. PubMed ID: 29996965
[TBL] [Abstract][Full Text] [Related]
12. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
[TBL] [Abstract][Full Text] [Related]
13. Observations following discontinuation of long-term denosumab therapy.
McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM
Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701
[TBL] [Abstract][Full Text] [Related]
14. Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.
Dempster DW; Brown JP; Fahrleitner-Pammer A; Kendler D; Rizzo S; Valter I; Wagman RB; Yin X; Yue SV; Boivin G
J Clin Endocrinol Metab; 2018 Jul; 103(7):2498-2509. PubMed ID: 29672714
[TBL] [Abstract][Full Text] [Related]
15. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
Tsourdi E; Langdahl B; Cohen-Solal M; Aubry-Rozier B; Eriksen EF; Guañabens N; Obermayer-Pietsch B; Ralston SH; Eastell R; Zillikens MC
Bone; 2017 Dec; 105():11-17. PubMed ID: 28789921
[TBL] [Abstract][Full Text] [Related]
17. Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis.
Popp AW; Varathan N; Buffat H; Senn C; Perrelet R; Lippuner K
Calcif Tissue Int; 2018 Jul; 103(1):50-54. PubMed ID: 29380013
[TBL] [Abstract][Full Text] [Related]
18. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
[TBL] [Abstract][Full Text] [Related]
19. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
20. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
